Is this study's primary condition wrong?
Trial of Palbociclib in Second Line of Advanced Sarcomas With CDK4 Overexpression.
- The registry's first term
- Sarcoma
- ClinicalTrials.gg shows
- Osteosarcoma
Trial of Palbociclib in Second Line of Advanced Sarcomas With CDK4 Overexpression.